Who is sponsoring NCT02614872?

NCT02614872 is sponsored by Kamada, Ltd..

What drugs are being tested in NCT02614872?

Interventions in NCT02614872: GLASSIA® and Institution standard of care (SOC).

What condition does NCT02614872 study?

NCT02614872 studies Transplantation, Lung Rejection.

Is NCT02614872 still recruiting?

NCT02614872 is currently completed. Last updated 1 September 2021.

Last reviewed 2021-09-01 · How we verify

NCT02614872

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

Completed Phase 2 Last updated 1 September 2021

What this trial tests

Phase 2 trial testing GLASSIA® and Institution standard of care (SOC) in Transplantation, Lung Rejection in 30 participants. Completed in 7 May 2019.

Timeline

26 July 2016

Primary endpoint
11 April 2019

7 May 2019

Quick facts

Lead sponsor	Kamada, Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	26 July 2016
Primary completion	11 April 2019
Estimated completion	7 May 2019
Sites	1 location across Israel

Drugs / interventions tested

GLASSIA® and Institution standard of care (SOC) — full drug profile →

Conditions studied

Transplantation, Lung Rejection — all drugs for Transplantation, Lung Rejection →

Sponsor

Kamada, Ltd. — full company profile →

Who can join

18 and older, any sex, with Transplantation, Lung Rejection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the safety and efficacy of intravenous GLASSIA® treatment in lung transplantation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients.
Baranovski BM, Schuster R, Nisim O, Brami I, et al · · 2018 · cited 8× · PMID 30723784 · DOI 10.15326/jcopdf.5.4.2017.0161
The COPD Pipeline XXX.
Gross N. · · 2015 · cited 1× · PMID 28848873 · DOI 10.15326/jcopdf.3.1.2015.0181

Verify or expand the search:

Other Kamada, Ltd. trials

Trials by the same sponsor.

NCT04550325 — Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19 · Phase 1, PHASE2 · completed
NCT02912845 — Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02614872 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kamada, Ltd.
Last refreshed: 1 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02614872.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing